secukinumab

Autoimmune drug pipeline: What health execs should watchNew drugs for RA, psoriasis, type 1 diabetes and Crohn’s disease—some recently approved and others coming down the pipeline—could have an impact on the industry.
Clear skin within reach for psoriasis patientsNew data presented at the 25th European Academy of Dermatology and Venereology (EADV) Congress in Vienna, Austria, this week shows that secukinumab (Cosentyx, Novartis) has long-lasting skin clearance in patients with moderate-to-severe plaque psoriasis.
Novartis announces new Cosentyx data in psoriasis treatment, including long-term studyResearchers presented new data on the use of the fully human IL-17A inhibitor Cosentyx (secukinumab, Novartis) in moderate-to-severe psoriasis, at the 25th European Academy of Dermatology and Venereology (EADV) Congress in Vienna, Austria, September 28 through October 2, 2016.
Secukinumab approved for psoriatic arthritis and ankylosing spondylitisNovartis announced January 15 that the FDA has approved secukinumab (Cosentyx, Novartis) for psoriatic arthritis (PsA) and active ankylosing spondylitis. The announcement comes a year after the FDA’s approval for secukinumab for treatment of adults with moderate to severe psoriasis. The drug is the only IL-17A antagonist approved for all three indications. learn more
Cosentyx gets thumbs up for 2 new indicationsFDA has approved secukinumab (Cosentyx, Novartis) for the treatment of adult patients with active ankylosing spondylitis and active psoriatic arthritis.
FDA approves secukinumab for psoriatic arthritisNovartis announced January 15 that the FDA approved Cosentyx (secukinumab) for psoriatic arthritis and active ankylosing spondylitis.
Can you maintain response after biologic holiday?Melinda Gooderham, M.D., MSc, FRCPC Patients might stop taking their biologic medications for a variety of reasons. When patients do stop their biologic therapy, clinicians need to consider that some biologic therapies are better at recapturing response than others. learn more
New psoriasis therapies must demonstrate valuePsoriasis affects a small percentage of the population but price increases for drug treatments have outpaced the Consumer Price Index.
Secukinumab shows benefit in psoriatic arthritis patientsSecukinumab may be an important new therapeutic treatment option for patients with psoriatic arthritis (PsA), according to a study published online in The New England Journal of Medicine.
Evidence-based guidance for psoriasis treatment
Evidence-based guidance for psoriasis treatmentNewer therapies to treat psoriasis and psoriatic arthritis are more likely to be successful in patients with no prior exposure to biologics. Traditional therapies remain an option but, unlike newer treatments, require monitoring for toxicities.